Comparative efficacy of probiotic mixture Bifidobacterium longum KABP042 plus Pediococcus pentosaceus KABP041 vs. Limosilactobacillus reuteri DSM17938 in the management of infant colic: a randomized clinical trial.

J M Moreno-Villares, D Andrade-Platas, M Soria-López, G Colomé-Rivero, A Catalan Lamban, M G Martinez-Figueroa, J Espadaler-Mazo, J Valverde-Molina

Journal: European journal of pediatrics 2024;183(12):5371-5381

PMID: 39390276

Abstract

UNLABELLED

We aimed to compare the efficacy of Bifidobacterium longum KABP042 + Pediococcus pentosaceus KABP041 (BL + PP) vs. Limosilactobacillus reuteri DSM17938 (LR) in alleviating the symptoms of infant colic, as commercially available formulations. A randomized, multicenter, parallel, single-blind (investigator) trial was conducted in 112 colicky infants diagnosed as per Rome IV criteria and randomly allocated to receive BL + PP orally (10 colony-forming units [CFU]/day, n = 55) or LR (10 CFU/day, n = 57) for 21 days. Primary study outcomes were percentage of responders (≥ 50% reduction in crying and fussing time from baseline, as reported by parents in a structured diary) and daily crying and fussing time (minutes/day) on days 7, 14, and 21 after randomization. Study groups were comparable at baseline. Responder rate was significantly higher in BP + PP group vs. LR group at days 7 (61.1% vs. 37.5%, p = 0.013) and 14 (84.6% vs. 59.3%, p = 0.004). Crying and fussing time (median [IQR]) became significantly lower in BL + PP group vs. LR group on day 7 (119 [60-210] vs. 180 [110-270]; p = 0.028), day 14 (60.0 [30-105] vs. 120 [60-180]; p = 0.017), and day 21 (29 [0-85] vs. 67 [30-165]; p = 0.011). No significant differences were found in the number of adverse events between the groups.

CONCLUSION

The specific formulation of B. longum KABP042 and P. pentosaceus KABP041 achieved a higher response rate and a larger reduction in crying and fussing time in colicky infants. Both probiotic interventions were well tolerated.

TRIAL REGISTRATION

The study was retrospectively registered as NCT05271747 on February 28th, 2022.

WHAT IS KNOWN

• L. reuteri DSM17938 (LR) is the most researched probiotic strain for infant colic against placebo in randomized, controlled clinical trials, and is recommended in various guidelines. A novel probiotic combining strains B. longum KABP042 and P. pentosaceus KABP041 (BL + PP) has also demonstrated efficacy in infant colic against placebo.

WHAT IS NEW

• This randomized study provides the first direct comparison of two probiotics for infant colic. BL + PP seems to be superior to LR in reducing crying time.

© 2024. The Author(s).

Address: Department of Pediatrics, Clínica Universidad de Navarra, Madrid, Spain.; Service of Pediatrics, Hospital Medica Sur, Mexico City, Mexico.; Gastroenterology and Pediatric Nutrition, Hospital HM Puerta del Sur, Madrid, Spain.; Digestive Service, Hospital HM Nens, Barcelona, Spain.; Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.; R&D Department, AB-Biotics SA (Kaneka Group), Barcelona, Spain. [email protected].; Department of Pediatrics, Hospital Universitario de Sta Lucia, Cartagena, Spain.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.